- cafead Feb 05, 2024 at 11:32: PM
via In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo.
GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK revealed in its 2023 annual and quarterly earnings report last week that sales of Arexvy totaled $1.5 billion or £1.2 billion in 2023, higher than its $1 billion estimation.
article source
GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK revealed in its 2023 annual and quarterly earnings report last week that sales of Arexvy totaled $1.5 billion or £1.2 billion in 2023, higher than its $1 billion estimation.
article source